Kensei Tobinai
#166,058
Most Influential Person Now
Researcher
Kensei Tobinai's AcademicInfluence.com Rankings
Kensei Tobinaicomputer-science Degrees
Computer Science
#9967
World Rank
#10456
Historical Rank
Machine Learning
#4503
World Rank
#4553
Historical Rank
Artificial Intelligence
#4861
World Rank
#4924
Historical Rank
Database
#6917
World Rank
#7158
Historical Rank
Download Badge
Computer Science
Kensei Tobinai's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science University of Tokyo
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Kensei Tobinai Influential?
(Suggest an Edit or Addition)Kensei Tobinai's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Revised response criteria for malignant lymphoma. (2007) (4137)
- Integrated molecular analysis of adult T cell leukemia/lymphoma (2015) (600)
- Frequent inactivation of A20 in B-cell lymphomas (2009) (559)
- Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. (2012) (553)
- Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. (2009) (499)
- VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. (2007) (417)
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (2019) (394)
- Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. (2011) (358)
- A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303 (2001) (357)
- Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. (2010) (338)
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. (2018) (330)
- Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. (2009) (308)
- Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. (2014) (302)
- Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. (2011) (293)
- Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. (1989) (282)
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (2018) (222)
- International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) (2017) (207)
- Peripheral T-cell lymphoma. (2011) (197)
- Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study (2015) (195)
- Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. (1993) (172)
- Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. (1998) (152)
- Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma (2000) (149)
- Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. (2013) (145)
- Establishment and characterization of 10 cell lines derived from patients with adult T-cell leukemia. (1983) (132)
- Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. (2018) (127)
- Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. (2002) (125)
- Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. (2012) (121)
- Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation (2001) (110)
- Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (2017) (105)
- Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2017) (105)
- Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. (2015) (103)
- A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies (2016) (102)
- Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. (2004) (100)
- Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. (2006) (100)
- A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma (2014) (99)
- Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan (2001) (99)
- Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. (2016) (96)
- Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. (2016) (94)
- Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. (2000) (82)
- Hyperglycemia During the Neutropenic Period Is Associated With a Poor Outcome in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (2007) (82)
- Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies (2015) (81)
- Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma. (1988) (81)
- Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. (2007) (76)
- Histology according to the Revised European-American Lymphoma Classification significantly predicts the prognosis of ocular adnexal lymphoma. (1999) (74)
- Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. (2006) (72)
- Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma (2017) (72)
- Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. (2019) (72)
- Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. (2002) (71)
- Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long‐term survivors of aggressive adult T‐cell leukaemia‐lymphoma (JCOG0902A) (2014) (71)
- Anti-ATLA (Antibody to the Adult T-Cell Leukemia Cell-Associated Antigen)-Positive Hematologic Malignancies in the Kanto District (1982) (68)
- Human T-cell Lymphotropic Virus Type I–Associated Adult T-cell Leukemia–Lymphoma: New Directions in Clinical Research (2014) (67)
- Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. (2019) (66)
- A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies (2018) (66)
- Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma (2010) (66)
- Adult T-cell leukemia/lymphoma not associated with human T-cell leukemia virus type I. (1986) (66)
- The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. (2009) (64)
- Multicenter phase II study of bendamustine for relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma (2010) (63)
- Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma (2007) (63)
- Genetic Alteration of p53 in Some Patients with Adult T‐Cell Leukemia (1991) (62)
- Phase I study of anti‐CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B‐cell non‐Hodgkin lymphoma (2012) (61)
- Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. (2011) (61)
- Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. (2008) (60)
- Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation. (2002) (60)
- Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. (2002) (58)
- Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes. (2014) (58)
- Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients. (2006) (57)
- Epidemiological and clinical features of adult T‐cell leukemia–lymphoma in Japan, 2010–2011: A nationwide survey (2017) (57)
- The landscape of new drugs in lymphoma (2017) (57)
- Phase I study of inotuzumab ozogamicin (CMC‐544) in Japanese patients with follicular lymphoma pretreated with rituximab‐based therapy (2010) (56)
- Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma (2017) (55)
- Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients. (2007) (55)
- Primary Mediastinal Lymphoma: Characteristic Features of the Various Histological Subtypes on CT (2004) (54)
- Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature (2008) (52)
- Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma (2017) (50)
- Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma (2006) (49)
- Clinicopathological features of histological transformation from extranodal marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue to diffuse large B‐cell lymphoma: an analysis of 467 patients (2016) (49)
- Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria. (2001) (49)
- CHEMOTHERAPY OF ATL (2003) (49)
- Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies (2017) (49)
- A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. (2011) (48)
- Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma (2014) (47)
- Epstein-Barr virus (EBV) genome carrying monoclonal B-cell lymphoma in a patient with adult T-cell leukemia-lymphoma. (1991) (45)
- Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma (2018) (45)
- Atypical adult T-cell leukemia-lymphoma: diverse clinical manifestations of adult T-cell leukemia-lymphoma. (1983) (45)
- Morphological spectrum of cyclin D1‐positive mantle cell lymphoma: Study of 168 cases (2001) (44)
- Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel (2018) (43)
- Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab (2001) (43)
- Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage (2013) (43)
- Diffuse large B‐cell lymphoma after transformation from low‐grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses (2008) (43)
- Proteasome inhibitor, bortezomib, for myeloma and lymphoma (2007) (42)
- Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. (2016) (42)
- The prognostic significance of lymphopenia in peripheral T‐cell and natural killer/T‐cell lymphomas: A study of 826 cases from the International Peripheral T‐cell Lymphoma Project (2012) (41)
- Monitoring of WT1‐specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation (2006) (41)
- Phase I study of tirabrutinib (ONO‐4059/GS‐4059) in patients with relapsed or refractory B‐cell malignancies in Japan (2019) (41)
- Phase I study of YK-176 (2'-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. The DCF Study Group. (1992) (41)
- Primary Hepatic Low-Grade B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: A Case Report and Review of the Literature (2002) (41)
- Expression pattern of PD‐L1 and PD‐L2 in classical Hodgkin lymphoma, primary mediastinal large B‐cell lymphoma, and gray zone lymphoma (2018) (38)
- Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B (2010) (38)
- Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma (2010) (38)
- Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I–II1, diffuse large B‐cell lymphoma of the stomach (2005) (38)
- Histological and immunophenotypic changes in 59 cases of B‐cell non‐Hodgkin's lymphoma after rituximab therapy (2009) (37)
- Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell Lymphomas (2012) (37)
- Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation (2017) (36)
- Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes (2011) (36)
- Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin’s Lymphomas: Results of a Japanese Phase II Study (2004) (36)
- Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. (2006) (36)
- Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial (2017) (36)
- Japanese phase II study of 90Y‐ibritumomab tiuxetan in patients with relapsed or refractory indolent B‐cell lymphoma (2009) (36)
- Phase II Study of Cladribine (2-Chlorodeoxyadenosine) in Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma (2003) (35)
- Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma (2012) (35)
- Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma. (2017) (35)
- Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma (2013) (34)
- Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non‐Hodgkin’s lymphoma 6 (2011) (33)
- The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (2021) (33)
- Follicular lymphoma of the duodenum: a clinicopathologic analysis of 26 cases. (2008) (33)
- t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs (2015) (33)
- Clinical Trials and Treatment of ATL (2012) (33)
- Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. (2007) (33)
- Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma (2016) (32)
- Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. (2011) (32)
- Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study. (2009) (31)
- Chromosome aberrations and clinical features of adult T cell leukemia-lymphoma not associated with human T cell leukemia virus type I. (1987) (31)
- Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas (2010) (30)
- Follicular lymphoma subgrouping by fluorescence in situ hybridization analysis (2005) (30)
- Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia (2009) (30)
- Biology and treatment of HTLV-1 associated T-cell lymphomas. (2013) (30)
- Bulky disease has an impact on outcomes in primary diffuse large B‐cell lymphoma of the breast: a retrospective analysis at a single institution (2011) (29)
- Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy. (2013) (29)
- Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study (2019) (29)
- Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation (2008) (29)
- First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results (2017) (29)
- Epstein–Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B‐cell lymphoma (2006) (28)
- Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy. (2014) (28)
- Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma (2015) (28)
- Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B‐cell lymphoma (2006) (28)
- Phase I study of LY2469298, an Fc‐engineered humanized anti‐CD20 antibody, in patients with relapsed or refractory follicular lymphoma (2011) (28)
- Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies (2015) (28)
- Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma (2017) (28)
- Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study (2009) (28)
- Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy (2010) (28)
- Current management of adult T-cell leukemia/lymphoma. (2009) (27)
- Infectious complications in chronic graft‐versus‐host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced‐ and conventional‐intensity conditioning regimens (2008) (26)
- Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study (2017) (26)
- Infectious states of human T lymphotropic virus type I and hepatitis B virus among Japanese immigrants in the Republic of Bolivia. (1988) (26)
- γδ T-cell neoplasms: a clinicopathological study of 11 cases (2002) (26)
- Phase III study to evaluate the use of high‐dose chemotherapy as consolidation of treatment for high‐risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208 (2007) (26)
- Mogamulizumab for the treatment of T-cell lymphoma (2017) (25)
- Brain involvement in Hodgkin's disease: case reports and review of the literature. (2000) (25)
- Diffuse Large B-Cell Lymphoma With Extra Bcl-2 Gene Signals Detected by FISH Analysis Is Associated With a “Non-Germinal Center Phenotype” (2005) (25)
- Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges (2019) (25)
- Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan. (2001) (25)
- Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation (2003) (25)
- Nutritional support for patients suffering from intestinal graft‐versus‐host disease after allogeneic hematopoietic stem cell transplantation (2006) (25)
- Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma (2010) (25)
- High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma (2003) (25)
- Multidrug Resistance in Cultured Human Leukemia and Lymphoma Cell Lines Detected by a Monoclonal Antibody, MRK16 (1989) (24)
- Prognosis of patients with adult T‐cell leukemia/lymphoma in Japan: A nationwide hospital‐based study (2020) (24)
- K-sam-related gene, N-sam, encodes fibroblast growth factor receptor and is expressed in T-lymphocytic tumors. (1992) (24)
- Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era (2014) (24)
- Development of new agents for peripheral T-cell lymphoma (2019) (24)
- Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies (2004) (24)
- Primary cutaneous aspergillosis caused by Aspergillus ustus following reduced-intensity stem cell transplantation (2002) (24)
- Significance of cyclin D 1 overexpression for the diagnosis of mantle cell lymphoma : a clinicopathologic comparison of cyclin D 1-positive MCL and cyclin D 1-negative MCL-like B-cell lymphoma (2000) (23)
- Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin (2002) (23)
- Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia–lymphoma in Japan: interim results of postmarketing all-case surveillance (2017) (23)
- Cardiac conduction abnormalities in patients with breast cancer undergoing high-dose chemotherapy and stem cell transplantation (2000) (23)
- Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma (2015) (23)
- E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma: A phase I study (2018) (22)
- Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial (2010) (22)
- Cellular Origin of Human Lymphoid Malignancies as Based on Immunologic Analysis of Membrane Differentiation Antigens (1982) (22)
- Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group. (1997) (22)
- Lymphoma study group of JCOG. (2012) (22)
- Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma. Lymphoma Study Group of the Japan Clinical Oncology Group. (1995) (22)
- A novel pre-T cell line derived from acute lymphoblastic leukemia. (1982) (21)
- PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). (2016) (21)
- Differences in clinicopathological characteristics and major prognostic factors between B-lymphoma and peripheral T-lymphoma excluding adult T-cell leukemia/lymphoma. (1993) (21)
- Adult T-cell leukemia–lymphoma: current treatment strategies and novel immunological approaches (2010) (21)
- Follow-up Data of 10 Patients With B-cell Non-Hodgkin Lymphoma With a CD20-negative Phenotypic Change After Rituximab-containing Therapy (2013) (20)
- Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T‐cell lymphoma (2012) (20)
- Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review (2018) (20)
- Impact of graft‐versus‐host disease in reduced‐intensity stem cell transplantation (RIST) for patients with haematological malignancies (2003) (20)
- Follow‐up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: impact on allogeneic haematopoietic stem cell transplantation (2019) (19)
- A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. (2020) (19)
- Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non‐Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study (2011) (19)
- Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer‐cell malignancies (2012) (19)
- Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome). (2009) (19)
- A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial (2013) (19)
- Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group. (1996) (18)
- Clinical trials for malignant lymphoma in Japan. (2004) (18)
- Bcl‐2, Bcl‐6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy (2012) (18)
- A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma (2016) (18)
- Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan (2002) (18)
- Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy (2014) (18)
- Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma (2018) (18)
- A novel monocytoid cultured cell line, P31/Fujioka, derived from acute monoblastic leukemia. (1982) (18)
- Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation. (2018) (18)
- Phase I study of radioimmunotherapy with an anti‐CD20 murine radioimmunoconjugate (90Y‐ibritumomab tiuxetan) in relapsed or refractory indolent B‐cell lymphoma (2005) (17)
- Phase I/II study of bortezomib‐melphalan‐prednisolone for previously untreated Japanese patients with multiple myeloma (2013) (17)
- Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines. (1999) (17)
- Targeting EZH2 with tazemetostat. (2018) (17)
- Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment (2017) (17)
- Enteropathy-type T-cell lymphoma showing repeated small bowel rupture and refractoriness to chemotherapy: a case report. (2002) (17)
- Multicenter Phase II Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, In Relapsed Patients with Adult T-Cell Leukemia-Lymphoma (ATL) (2010) (17)
- An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant (2019) (17)
- Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study. (2006) (16)
- Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma (2016) (16)
- Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B‐cell non‐Hodgkin lymphoma: 7‐year follow‐up results (2010) (16)
- Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma (2003) (16)
- Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. (2009) (16)
- A Randomized Controlled Trial Investigating the Survival Benefit of Dose-Intensified Multidrug Combination Chemotherapy (LSG9) for Intermediate- or High-Grade Non-Hodgkin’s Lymphoma: Japan Clinical Oncology Group Study 9002 (2004) (16)
- Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic haematopoietic stem cell transplantation from an ABO‐incompatible donor (2002) (16)
- Detection of t(I 1; 18) in MALT-type lymphoma with dual-color fluorescence in situ hybridization and reverse transcriptase-polymerase chain reaction analysis. (2001) (16)
- Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: PET/CT (2010) (15)
- Distribution of malignant lymphomas in the anterior mediastinum: a single-institution study of 76 cases in Japan, 1997–2016 (2017) (15)
- Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study (2017) (15)
- Prevalence of antibodies to human T-cell leukemia/lymphoma virus type I and human immunodeficiency virus in Japanese immigrant colonies in Bolivia and Bolivian natives. (1987) (15)
- Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan (2010) (15)
- Nocardia exalbida brain abscess in a patient with follicular lymphoma (2008) (15)
- Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma (1988) (15)
- Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. (2018) (15)
- Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL). (2013) (15)
- Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor. (1995) (15)
- Long-term Follow-up Results of Adult Patients with Acute Lymphocytic Leukemia or Lymphoblastic Lymphoma Treated with Short-term, Alternating Non-cross-resistant Chemotherapy: Japan Clinical Oncology Group Study 8702 (1999) (14)
- Phase II study of ABVd therapy for newly diagnosed clinical stage II–IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305) (2010) (14)
- Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL). (2014) (14)
- A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial (2016) (14)
- A Novel Multidrug Resistance in Cultured Leukemia and Lymphoma Cells Detected by a Monoclonal Antibody to 85‐kDa Protein, MRK20 (1989) (14)
- Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan. (1996) (14)
- T-cell large granular lymphocyte leukemia of donor origin after cord blood transplantation. (2007) (14)
- Disseminated herpes zoster infection initially presenting with abdominal pain in patients with lymphoma undergoing conventional chemotherapy: A report of three cases (2016) (14)
- Early onset Pneumocystis carinii pneumonia after allogeneic peripheral blood stem cell transplantation (2001) (14)
- Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B‐cell lymphoma associated with follicular lymphoma, or de novo diffuse large B‐cell lymphoma (2012) (14)
- A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma (2015) (14)
- Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study (2005) (13)
- Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma (2020) (13)
- Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group study 9004 (2007) (13)
- A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia (2013) (13)
- Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan (2017) (13)
- Treatment of Indolent Non-Hodgkin’s Lymphoma with Cladribine as Single-Agent Therapy and in Combination with Mitoxantrone (2004) (13)
- Unrelated-Donor Bone Marrow Transplantation with a Conditioning Regimen Including Fludarabine, Busulfan, and 4 Gy Total Body Irradiation (2007) (13)
- Primary Mediastinal Large B-Cell Lymphoma: A Single-Institution Clinical Study in Japan (2004) (13)
- Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma. (2018) (13)
- IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN (2017) (13)
- Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma (2015) (13)
- Anti-ATLA (antibody to adult T-cell leukemia-lymphoma virus-associated antigen)-negative adult T-cell leukemia-lymphoma. (1983) (13)
- Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) – Results From Two Phase I Studies (2010) (13)
- Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma (2016) (13)
- Two Entities of Precursor T-Cell Lymphoblastic Leukemia/Lymphoma Based on Radiologic and Immunophenotypic Findings (2004) (13)
- Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan (2001) (12)
- Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma (2017) (12)
- Two novel cultured cell lines, A3/Kawakami and A4/Fukuda, derived from malignant lymphoma of B(non-T)-cell nature of the gastrointestinal tract. (1983) (12)
- Clinicopathological characteristics of follicular lymphoma with peripheral blood involvement (2015) (12)
- Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study (2011) (12)
- Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma (2021) (12)
- Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma (2021) (12)
- Clinicopathological features of classical Hodgkin lymphoma in patients ≥ 40 years old, with special reference to composite cases. (2015) (12)
- First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL) (2019) (12)
- Phase I/II Study of Concurrent Chemoradiotherapy for Newly-Diagnosed, Localized Nasal NK/T-Cell Lymphoma: Results of a Phase I Portion of JCOG0211-DI. (2005) (12)
- Rituximab and other emerging monoclonal antibody therapies for lymphoma (2002) (12)
- The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma (2020) (11)
- Safety and effectiveness of mogamulizumab in relapsed or refractory adult T‐cell leukemia‐lymphoma (2019) (11)
- Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy (2016) (11)
- Anti-ATLA (antibody to adult T-cell leukemia virus-associated antigen), highly positive in OKT4-positive mature T-cell malignancies. (1983) (11)
- Gamma delta T-cell neoplasms: a clinicopathological study of 11 cases. (2002) (11)
- Thrombotic microangiopathy of hyperacute onset after autologous peripheral blood stem cell transplantation in malignant lymphoma (1998) (11)
- An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. (2022) (11)
- Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (2013) (10)
- Abdominal pain and syndrome of inappropriate antidiuretic hormone secretion as a manifestation of visceral varicella zoster virus infection in a patient with non‐Hodgkin's lymphoma (2007) (10)
- Molecular genetic and immunohistochemical analyses of a case of multicentric Castleman's disease. (1988) (10)
- Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma (2008) (10)
- Histopathological analysis of B-cell non-Hodgkin lymphomas without light chain restriction by using flow cytometry (2015) (10)
- Tirabrutinib hydrochloride for B-cell lymphomas. (2021) (9)
- A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. (2003) (9)
- A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). (2012) (9)
- Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma (2016) (9)
- Putting the Clinical and Biological Heterogeneity of Non-Hodgkin Lymphoma into Context (2014) (9)
- Multicenter Phase I Dose-Escalation Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL). (2012) (9)
- Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients. (2002) (9)
- Mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results (2019) (9)
- Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan. (2010) (9)
- Carcinoma of Donor Origin After Allogeneic Peripheral Blood Stem Cell Transplantation (2012) (9)
- Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial (2018) (9)
- Comparison of clinicopathologic characteristics of gastric follicular lymphomas and duodenal follicular lymphomas. (2017) (9)
- Cellular Origin of T Cell Malignancies (1982) (8)
- R‐High‐CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY (2018) (8)
- Development and Molecular Analysis of Synthetic Lethality By Targeting EZH1 and EZH2 in Non-Hodgkin Lymphomas (2016) (8)
- NK-Cell Neoplasms (2013) (8)
- Adult T-cell leukemia-lymphoma successfully treated with 2-chlorodeoxyadenosine. (1998) (8)
- Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma (2016) (8)
- B-cell lymphoma accompanying monoclonal macroglobulinemia with features suggesting marginal zone B-cell lymphoma. (1997) (8)
- Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B‐cell non‐Hodgkin lymphoma (2009) (8)
- Clinicopathological prognostic indicators in 107 patients with diffuse large B‐cell lymphoma transformed from follicular lymphoma (2013) (8)
- Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma (2020) (8)
- An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma, (2011) (8)
- CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib (2021) (8)
- Phase I and Pharmacokinetic Study of Inotuzumab Ozogamicin (CMC- 544) as a Single Agent in Japanese Patients with Follicular Lymphoma Pretreated with Rituximab. (2008) (8)
- Randomized Comparison of Mobilization Kinetics of Circulating CD34+ Cells Between Biweekly CHOP and Dose-Escalated CHOP with the Prophylactic Use of Lenograstim (Glycosylated rHuG-CSF) in Aggressive Non-Hodgkin's Lymphoma (2000) (7)
- Cytocidal activity of PBL, LAK, and IDEC-C2B8 and expression of HLA class 1, ICAM-1, and CD20 in vincristine-resistant hematologic cell lines. (1999) (7)
- The Reaction Specificity of Various Monoclonal Antibodies and Cellular Origin and Differentiation of Cultured Cell Lines Derived from Human Leukemias and Lymphomas (1981) (7)
- Concurrent adult T-cell leukemia and acute myeloblastic leukemia. (1988) (7)
- Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea (2020) (7)
- Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma (2020) (7)
- Phase I/II and pharmacokinetic study of cladribine with 2‐h infusion in Japanese patients with relapsed indolent B‐cell lymphoma mostly pretreated with rituximab (2009) (7)
- Bendamustine Is Highly Effective for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mantle Cell Lymphoma (MCL): Final Results of a Japanese Multicenter Phase II Study. (2009) (7)
- Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. (2006) (7)
- Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. (2011) (7)
- Phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients (pts) with non-Hodgkin lymphoma (NHL) in Japan (2007) (7)
- Granular lymphocytic leukemia derived from γδ T-cell expressing cytotoxic molecules (2001) (7)
- Phase I Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts) with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL): Updated Results. (2008) (7)
- Histopathological Characteristics of Lymphomas in the Upper Aerodigestive Tract. A Single-Institute Study in Japan. (2015) (7)
- A Dose-finding Study of Lenograstim (Glycosylated rHuG-CSF) for Peripheral Blood Stem Cell Mobilization during Postoperative Adjuvant Chemotherapy in Patients with Breast Cancer (1999) (7)
- Severe herpes simplex virus hepatitis following autologous bone marrow transplantation: successful treatment with high dose intravenous acyclovir. (1991) (7)
- CD56-positive small round cell tumor: osseous plasmacytoma manifested in osteolytic tumors of the iliac bone and femora. (2005) (7)
- Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): An interim analysis. (2016) (7)
- Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis (2020) (7)
- The Application of Molecular Analyses for Primary Granulocytic Sarcoma with a Specific Chromosomal Translocation (2005) (7)
- Phase II/III Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab (R-CHOP) Versus Biweekly CHOP with Rituximab (R-Bi-CHOP) In Untreated Advanced-Stage Indolent B-Cell Lymphoma: Japan Clinical Oncology Group (JCOG) 0203 Trial (2010) (7)
- DS-3201, a Potent EZH1/2 Dual Inhibitor, Demonstrates Antitumor Activity Against Non-Hodgkin Lymphoma (NHL) Regardless of EZH2 Mutation (2018) (7)
- Intravascular large B-cell lymphoma secondary to lymphoplasmacytic lymphoma: a case report and review of literature with clonality analysis. (2015) (7)
- Phase I and Pharmacokinetic (PK) Study of Everolimus (RAD001) in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL). (2009) (7)
- Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (2016) (7)
- Phase 1/2 study of forodesine in patients with relapsed peripheral t-cell lymphoma (PTCL). (2016) (6)
- Partial deletion of the ALK gene in ALK‐positive anaplastic large cell lymphoma (2018) (6)
- Monoclonal antibody studies in B(non-T)-cell malignancies. (1983) (6)
- Novel Interleukin‐2 Dependent T‐Cell Line Derived from Adult T‐Cell Leukemia Not Associated with Human T‐Cell Leukemia Virus Type I (1993) (6)
- Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-Cell Leukemia-Lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801. (2005) (6)
- Phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: Final results of JCOG0211. (2016) (6)
- A Phase II Study of VEPA/FEPP Chemotherapy for Aggressive Lymphoma in Elderly Patients: Japan Clinical Oncology Group Study JCOG9203 (2006) (6)
- Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low–intermediate risk, aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508 (2012) (6)
- Phase 1 Study of Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Japanese Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (2010) (6)
- Detection of t(11;18) in MALT-Type Lymphoma With Dual-Color Fluorescence In Situ Hybridization and Reverse Transcriptase–Polymerase Chain Reaction Analysis (2001) (6)
- Follicular lymphoma with marked monocytoid or plasmacytoid differentiation and tiny or indistinct follicles: a case study of four patients (2011) (6)
- Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study (2019) (6)
- Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma (2015) (6)
- A phase I pharmacokinetic and safety study of polatuzumab vedotin in Japanese patients with relapsed/refractory b-cell non-Hodgkin lymphoma: A comparison with non-Japanese DCS4968g study. (2016) (6)
- A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. (2021) (6)
- Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia (2017) (6)
- Incidental detection of malignant lymphoma in subjects in a cancer surveillance programme (2015) (6)
- Is zidovudine and interferon-alfa the gold standard for adult T-cell leukemia-lymphoma? (2010) (6)
- Promising results of an anti-CCR4 antibody, KW-0761, for relapsed Adult T-Cell Leukemia-Lymphoma (ATL) (2011) (6)
- Oral HDAC Inhibitor HBI8000 in Japanese Patients with Non-Hodgkin Lymphoma (NHL): Phase I Safety and Efficacy Results (2016) (6)
- A novel Japanese Burkitt's lymphoma cell line, P32/Ishida, with a new variant chromosomal translocation (2;14). (1983) (6)
- Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial (2018) (6)
- Ewing sarcoma arising after treatment of diffuse large B-cell lymphoma. (2013) (6)
- Prolonged Lymphocytepenia after Bendamustine with or without Rituximab Treatment in Patients with Relapsed or Refractory Indolent B-Cell and Mantle Cell Lymphoma (2014) (5)
- Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma (2016) (5)
- Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma (2019) (5)
- [Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL]. (2011) (5)
- Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome (2017) (5)
- Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705) (2013) (5)
- Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor. (2018) (5)
- Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients (2010) (5)
- Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma (2018) (5)
- A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma (2019) (5)
- Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402. (2012) (5)
- Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (2016) (5)
- Delayed recovery of neutrophil counts after peripheral stem cell transplantation which improved with administration of a minimal dose of G-CSF: a case report. (2001) (5)
- Hemorrhagic cystitis associated with allogeneic and autologous bone marrow transplantation for malignant neoplasms in adults. (1993) (5)
- [Frequent inactivation of A20 through gene mutation in B-cell lymphomas]. (2011) (5)
- Chemotherapy: the more, the better in malignant lymphoma? (1997) (4)
- Prognosis of non-Hodgkin's lymphoma 1. T- and B-lymphoma and its primary site.:1. T- and B-lymphoma and its primary site (1985) (4)
- Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma. (2016) (4)
- Immunoblastic lymphadenopathy (IBL)-like T-cell lymphoma: clinico-pathologic, immunophenotypic and immunogenotypic analyses. (1987) (4)
- Age-Related Risk of Non-Relapse Mortality Associated with Acute Graft-Versus-Host Disease. (2006) (4)
- Treatment of hairy cell leukemia with deoxycoformycin (YK-176). The Deoxycoformycin (YK-176) Study Group. (1992) (4)
- Phase I Study of KW-0761, a Humanized Anti-CCR4 Antibody, in Patients (Pts) with Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma (ATLL) and Peripheral T-Cell Lymphoma (PTCL): Preliminary Results. (2007) (4)
- Subcutaneous rituximab: a practical approach? (2014) (4)
- Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma (2021) (4)
- Disease‐oriented treatment of T‐cell lymphoma (2017) (4)
- 90Y Ibritumomab Tiuxetan (Y2B8, Zevalin®) Radioimmunotherap (RIT) Is Highly Effective for Relapsed or Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (B-NHL) Pretreated with Rituximab-Containing Chemotherapy (R-Chemo): Japanese Multicenter Phase II Study. (2006) (4)
- Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma (2021) (4)
- Epstein-Barr virus-associated enteropathy as a complication of infectious mononucleosis mimicking peripheral T-cell lymphoma. (2013) (4)
- The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma (2016) (4)
- Analysis of myelodysplastic syndrome clones arising after multiple myeloma: a case study by correlative interphase cytogenetic analysis. (1999) (4)
- Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2 (2022) (4)
- Detection of Loss of A20 Gene by FICTION in Hodgkin's Lymphoma Cases. (2009) (4)
- Cross-Sectional Patient Survey on the Need for a Long-Term Follow-up Program after Autologous Hematopoietic Cell Transplantation (2016) (3)
- Successful allogeneic bone marrow transplantation in a case of adult precursor B-lymphoblastic lymphoma. (2000) (3)
- Rituximab biosimilars: introduction into clinical practice. (2017) (3)
- Adult T-Cell Leukemia-Lymphoma. (2018) (3)
- Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma (2020) (3)
- Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CCR4 Antibody, in Patients with Relapsed Peripheral and Cutaneous T-Cell Lymphoma (2012) (3)
- Antibodies to human immuno-deficiency virus and human T-cell leukemia virus type I in Japanese patients with hematologic malignancies. (1986) (3)
- Genome-Wide Analysis of B Cell Non-Hodgkin’s Lymphoma Disclosed Frequent Involvement of Genes in NFkB Pathway (2008) (3)
- [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)]. (2002) (3)
- Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial (2019) (3)
- FUS-ERG gene fusion in isolated myeloid sarcoma showing uncommon clinical features (2016) (3)
- The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (2018) (3)
- Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study (2019) (3)
- Clinicopathologic Analysis of Follicular Lymphoma (FL) Patients with Coexisting Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Rituximab-Containing Chemotherapy (2012) (3)
- Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (2016) (3)
- Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study (2021) (3)
- Characterization of Long-Term Survivors and a Predictive Model for Aggressive Adult T-Cell Leukemia-Lymphoma (ATL): An Ancillary Study by the Japan Clinical Oncology Group, JCOG0902A (2011) (3)
- A Retrospective Single Institute Analysis of 127 Lymphoma Patients Who Underwent Allogeneic Stem Cell Transplantation: Impact on Peripheral T-Cell Lymphoma (PTCL) Including ATLL. (2006) (3)
- Reply to R. Suzuki (2010) (3)
- 4. Antibody therapy for malignant lymphoma. (2007) (3)
- Oral histone deacetylase inhibitor tucidinostat (HBI‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase IIb results (2022) (3)
- Post-Marketing Surveillance of Bortezomib Treatment for Multiple Myeloma (MM) in Japan: Results of Interim Analysis by the Velcade Japan Proper Use Guideline Committee (2008) (3)
- Upfront Radiotherapy with Concurrent Chemotherapy for Localized Nasal NK/T-Cell Lymphoma: Radiotherapy Quality Assurance (QA) Review in Japan Clinical Oncology Group (JCOG) Trial 0211 (2008) (3)
- Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study (2019) (3)
- Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin’s lymphoma: phase I safety and efficacy (2022) (3)
- Pralatrexate: Phase 1/2 Study in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) (2016) (3)
- Third annual forum on T-cell lymphoma (2011) (3)
- Phase I study of a novel humanized anti-CD20 antibody, BM-ca, in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab. (2013) (3)
- [A novel cultured cell line (P30/Ohkubo) of pre-T cell (C/T hybrid) phenotype derived from an acute lymphoblastic leukemia with some phenotypic change during clinical course]. (1983) (2)
- Randomized phase II study of concurrent and sequential combinations of rituximab (R) plus CHOP (R-CHOP) in untreated indolent B-NHL: 7-year follow-up results (2008) (2)
- Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (2021) (2)
- Successful treatment of a primary gastric T-cell lymphoma lacking the human T-cell leukemia virus type 1. (2010) (2)
- [Prognosis of non-Hodgkin's lymphoma. 3. Clinical and pathological diagnosis of T- and B-lymphoma and its staging]. (1985) (2)
- Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma (2020) (2)
- [Recent advances in clinical research on T-cell lymphoma]. (1990) (2)
- Diagnosis and evaluation of intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation following reduced-intensity and myeloablative conditioning regimens (2013) (2)
- Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group. (1999) (2)
- A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia (2020) (2)
- HTLV-1-Associated T-cell Diseases (2013) (2)
- [Prognosis of non-Hodgkin's lymphoma. 2. T- and B-lymphoma and clinical stage]. (1985) (2)
- [Central nervous system relapse with multiple brain masses in an acute promyelocytic leukemia patient treated with all-trans retinoic acid]. (1999) (2)
- SY1. building the foundation for investigator-initiated clinical trial (2012) (2)
- Long-term follow-up results of a phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma (NKTCL): JCOG0211. (2012) (2)
- Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features. (2002) (2)
- Durable Responses with Bendamustine Monotherapy In Patients with Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mantle-Cell Lymphoma (MCL): Updated Follow-up Data From a Japanese Multicenter Phase II Study (2010) (2)
- Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Bortezomib (B) in Patients (pts) with Relapsed Multiple Myeloma (MM): A Phase I/II Study in Japan. (2006) (2)
- Reassessment of non-hodgkins's lymphoma with a "nodular" growth variant: a clinicopathologic study of follicular, mantle cell and marginal zone lymphomas prospectively diagnosed with multiparameter analyses. (1998) (2)
- [Recent progress in the chemotherapy of malignant lymphoma]. (1995) (2)
- A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group. (1999) (2)
- Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study (2022) (2)
- Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma (2015) (2)
- Phase 1b and Pharmacokinetic Study of Idelalisib in Japanese Patients with Relapsed or Refractory (R/R) Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) or Chronic Lymphocytic Leukemia (CLL) (2015) (2)
- A PHASE 2B OPEN‐LABEL SINGLE ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HBI‐8000 (TUCIDINOSTAT) IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA (PTCL) (2021) (2)
- Randomized Phase II Study of R-CHOP-14 Versus R-CHOP-14 Followed By Chaser As Induction Therapy for High-Dose Chemotherapy (HDT), LEED, and Autologous Stem-Cell Transplantation (ASCT) in Poor-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Japan Clinical Oncology Group (JCOG) Study (JCOG0908) (2017) (2)
- Low-Dose ATG-F Reduces Non-Relapse Mortality after Reduced-Intensity Bone Marrow Transplantation from an Unrelated Donor: A Single-Center Analysis of 65 Patients. (2007) (1)
- Phase II study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed indolent B-cell lymphoma (1999) (1)
- An integrated manual for hematologists and dermatologists to access the guidelines for the management of adult T-cell leukemia-lymphoma (2014). (2014) (1)
- Phase I study of ofatumumab (OFA) in Japanese patients (JPN pts) with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). (2010) (1)
- Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study (2020) (1)
- Comparison of the International Workshop Criteria and the Response Evaluation Criteria in Solid Tumors for indolent B-cell lymphoma (2020) (1)
- Disease-oriented treatment of T/NK-cell lymphomas. (2016) (1)
- Endoscopic features of colorectal lymphoma according to histological type (2022) (1)
- Delayed hemolytic transfusion reactions during past ten years. (1993) (1)
- Prognostic significance of immunophenotypes and a nodular pattern in primary mediastinal large B‐cell lymphoma (2014) (1)
- Lipidomic Profiling of Plasma Samples in Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study for Predicting the Response and Toxicities of Melphalan, Prednisolone and Bortezomib (MPB) Regimen : An Ancillary Study of the JCOG1105 (JCOG1105A1) (2019) (1)
- Immunologic Phenotype of Tumor Cells from Japanese T Cell Malignancies (1984) (1)
- Two Phase I and Pharmacokinetic Studies of Darinaparsin (Organic Arsenic Compound) in Japanese and Korean Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) (2015) (1)
- Peripheral T-Cell Lymphoma-Unspecified (PTCL-U) and NK/T-Cell Lymphoma Showed a Significantly Poor Prognosis in a Randomized Controlled Trial (RCT) JCOG9002 with Multidrug Combination Chemotherapy for Aggressive Lymphoma. (2006) (1)
- Phase I Study of Forodesine (BCX1777), An Oral PNP Inhibitor In Patients with Relapsed or Refractory T/NK Malignancies. (2010) (1)
- Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma (2017) (1)
- [Detection of multidrug resistant phenotype in leukemia and lymphoma by monoclonal antibodies]. (1988) (1)
- The Response Evaluation Criteria in Solid Tumors Can be Substituted for the International Workshop Criteria?: Comparison Using Japan Clinical Oncology Group Study JCOG0203 for Untreated Indolent B-Cell Lymphoma (2016) (1)
- [The progress in treatment for malignant lymphomas and the future direction]. (2014) (1)
- Role of FDG-PET/CT in the Staging of Patients with Follicular Lymphoma (2015) (1)
- Standard CHOP therapy for low (L) or low-intermediate (L-I) risk patients (pts) with aggressive non-Hodgkin's lymphoma (NHL): A multicenter phase II study by Japan Clinical Oncology Group (JCOG 9508). (2004) (1)
- Deletion of the TNFAIP3/A20gene detected by FICTION analysis in classical Hodgkin lymphoma (2012) (1)
- [Analysis of membrane-associated antigen of human lymphatic neoplasms and its cellular origin using various monoclonal antibodies]. (1982) (1)
- Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. (2020) (1)
- [HTLV-I negative adult T cell leukemia; a case report of acute type]. (1993) (1)
- [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma]. (2007) (1)
- [Assessment for the image interpretation of 111In-ibritumomab tiuxetan in the phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma]. (2008) (1)
- [Development of novel therapeutic agents for adult T-cell leukemia-lymphoma]. (2012) (1)
- Japanese multicenter phase II study of CHOP followed by radiotherapy (RT) in stage I-II1 diffuse large B-cell lymphoma (DLBCL) of the stomach. (2004) (1)
- Ph-positive acute lymphoblastic leukemia after long-term remission of Ph-positive acute myeloid leukemia. (2007) (1)
- Primary ocular adnexal MALT lymphoma (POAML): A long-term follow up study of 114 patients (pts). (2006) (1)
- Comparative effectiveness study of chemotherapy in follicular lymphoma patients in the rituximab era: a Japanese claims database study. (2020) (1)
- Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study (2018) (1)
- Hematopoietic Cell Transplantation (HCT) for Chemoradiotherapy-Related Myelodysplastic Syndrome and Acute Leukemia: A Single-Center Analysis of 47 Patients. (2007) (1)
- AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R2) versus placebo plus rituximab. (2015) (1)
- Correction to: Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma (2018) (1)
- [Recent progress in the treatment of malignant lymphoma]. (1994) (1)
- Granular lymphocytic leukemia derived from gamma delta T-cell expressing cytotoxic molecules. (2001) (1)
- t(11;18)-Bearing Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Responding to Cladribine (2004) (1)
- Hyperglycemia during Neutropenia Was Associated with the Risk of Infection and Organ Dysfunction in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). (2006) (1)
- Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients (2020) (1)
- Clinical implications of anti-HTLV antibody titer, abnormal lymphocytes in HTLV carriers and HTLV genome negative adult T-cell leukemia-lymphoma. (1984) (1)
- Phase 1/2 Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Venetoclax in Japanese Subjects with Chronic Lymphocytic Leukemia (2017) (1)
- Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors (2020) (1)
- P2-22-2VISCERALLY DISSEMINATED HERPES ZOSTER PRESENTING ABDOMINAL PAIN, SIADH, AND SKIN RASH IN A FOLLICULAR LYMPHOMA PATIENT (2014) (1)
- A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL). (2012) (1)
- [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody]. (2002) (1)
- [A clinical study of non-Hodgkin's lymphoma of the nasal cavity and paranasal sinus]. (1988) (1)
- Epstein–Barr virus-negative high grade B cell lymphoma of donor origin developing 19 months after unrelated allogeneic bone marrow transplantation (2000) (1)
- Phase II Study of Chemotherapy (Cx) and Stem Cell Transplantation (SCT) for Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LBL): Long-Term Follow-up Results of Japan Clinical Oncology Group (JCOG) Study 9402. (2009) (1)
- [Establishment of a novel cultured cell line, P31/Fujioka, of monocytoid nature]. (1983) (1)
- Diagnosis and Treatment of Malignant Lymphoma (2008) (1)
- Safety and Tolerability of Obinutuzumab (GA101) with Shorter Duration of Infusion in Japanese Patients with Previously Untreated CD20-Positive B-Cell Non-Hodgkin's Lymphoma (NHL)-Comparison with GAO4915g (GATHER) and BO21005 (GOYA) Studies (2016) (1)
- [Tumor markers--personal experience. A case of advanced extragonadal germ-cell tumor showing complete remission by high-dose combination chemotherapy with autologous bone marrow transplantation]. (1991) (1)
- [Two novel cultured cell lines, A3/Kawasaki and A4/Fukuda, derived from malignant lymphomas of the gastrointestinal tract]. (1983) (1)
- Phase I study of bendamustine combined with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL). (2010) (1)
- [New trends in the diagnosis and treatment of malignant lymphoma]. (2003) (1)
- R‐CHOP‐14 versus R‐CHOP‐14/CHASER for upfront autologous transplantation in diffuse large B‐cell lymphoma: JCOG0908 study (2020) (1)
- Safety , efficacy and pharmacokinetics of humanized anti-CD 52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia (2016) (1)
- Dasatinib phase I/II study of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib: Results of the CA180031 study in Japan (2007) (1)
- Frequent Activating Somatic Alterations in T-Cell Receptor / NF-κb Signaling in Adult T-Cell Leukemia/Lymphoma (2015) (1)
- Role of FDG-PET/CT and gastrointestinal endoscopy in the staging of diffuse large B-cell lymphoma (DLBCL): Expanded data. (2016) (1)
- Hematopoietic Cell Transplantation-Specific Comorbidity Index To Predict Non-Relapse Mortality and Survival after Allografting. (2005) (1)
- 288ORole of FDG-PET/CT and gastrointestinal endoscopy in the staging of diffuse large B-cell lymphoma (DLBCL) (2015) (1)
- Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan (2003) (1)
- Clinicopathological Prognostic Indicators Of 24 Patients With B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma (2013) (1)
- EZH1/2, SWI/SNF, and MLL2 Dependent Heterochromatin Formation and Abnormal Transcriptome in Hematological Malignancies (2017) (0)
- Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma (2021) (0)
- Treatment of B cell lymphoma by monoclonal antibody. (2001) (0)
- 262: Prospective Monitoring of Nutritional Status During the Early Phase after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (2008) (0)
- Clinical and pathological features of primary lymphoma of bone (2008) (0)
- Health Economic Burden and Treatment-Based Survival for Current Follicular Lymphoma Treatment Practice in Japan Using a Nationwide Retrospective Claims Database (2019) (0)
- The role of local radiotherapy following rituximab‐containing chemotherapy in patients with transformed indolent B‐cell lymphoma (2020) (0)
- [Analysis of membrane differentiation antigens and ATLA (adult T-cell leukemia virus-associated antigen) of 25 cultured cell lines derived from human T-cell leukemia/lymphoma]. (1984) (0)
- Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia–lymphoma (2022) (0)
- MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan (2015) (0)
- An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data (2012) (0)
- New Agents of Adult T-cell Leukemia/Lymphoma (ATL) (2017) (0)
- Guest editorial: Management of malignant lymphoma is continuously improving (2012) (0)
- A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma (2016) (0)
- Prognostic Analysis of Hodgkin Lymphoma (HL) in JAPAN (2008) (0)
- Low Serum Total Protein and Unfavorable Pathological Subtype Are Independent Unfavorable Factors in Peripheral T-Cell Lymphoma (PTCL) Treated in Prospective Clinical Tirals; Japan Clinical Oncology Group (JCOG) 0108A Study. (2007) (0)
- リツキシマブ含有化学療法(R‐Chemo)で前処理されている再発性もしくは耐性の無痛性B細胞非ホジキンスリンパ腫(B‐NHL)に対して非常に効果的であるY‐90イブリツモマブチウキセタン(Y2B8、ゼヴァリン(R))放射免疫療法(RIT):日本多施設第II相試験 (2006) (0)
- Phase I and pharmacokinetics study of a novel anti-CD20 antibody, RO5072759 (GA101), in Japanese patients (Pts) with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab. (2010) (0)
- Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of an Asian Phase 2 Study. (2023) (0)
- Day +11 Methotrexate (MTX) Might Reduce the Risk of Engraftment Syndrome (ES) and Acute Graft-Versus-Host Disease (GvHD) After Unrelated Bone Marrow Transplantation (U-BMT) With Reduced-Intensity Conditioning Regimens (2011) (0)
- Pre-Engraftment Serum C-Reactive Protein (CRP) Value as a Predictor of Acute Graft-Versus-Host Disease and Non-Relapse Mortality. (2007) (0)
- Phase II Study of Intensive Post-remission Chemotherapy and Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma : Japan Clinical Oncology Group Study , JCOG 9402 (2012) (0)
- Outcomes among Patients with Relapsed Malignant Lymphoma after Allogeneic Hematopoietic Stem Cell Transplantation (2008) (0)
- [High dose chemotherapy followed by hematopoietic stem cell transplantation for malignant lymphoma]. (1995) (0)
- A clinicopathologic study of primary mediastinal large B-cell lymphoma (MLBCL) at a single institution in Japan. (2004) (0)
- Follow-Up of WT1-Specific Cytotoxic T Lymphocytes (CTL) with Tetramer-Based Analysis after Allogeneic Stem Cell Transplantation (SCT) in Patients with Renal Cell Carcinoma (RCC). (2004) (0)
- [Diagnosis and treatment of malignant lymphoma: discussion]. (2008) (0)
- A Clinical Pharmacology and Exploratory Study of Azacitidine Administered Subcutaneously or Intravenously In Japanese Patients with Myelodysplastic Syndrome (2010) (0)
- [Abnormal lymphocytes in HTLV infections and its clinical significance]. (1986) (0)
- [Rapid tapering of cyclosporine for cytogenetic relapse shortly after bone marrow transplantation in a patient with chronic myeloid leukemia]. (1998) (0)
- A Multicenter Phase II Study of Bendamustine with Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (2012) (0)
- Faculty Opinions recommendation of CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. (2013) (0)
- Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma (2022) (0)
- cyclin D1-negative MCL-like B-cell lymphoma lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and Significance of cyclin D1 overexpression for the diagnosis of mantle cell (2013) (0)
- Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma (2015) (0)
- An integrated analysis of hyponatremia in cancer patients receiving platinum-based chemotherapy in clinical trials (JCOG1405-A) (2016) (0)
- Durable Remission with Decreased HTLV-I Proviral Load after Reduced-Intensity Stem Cell Transplantation (RIST) in Patients with Adult T-Cell Leukemia/Lymphoma (ATL). (2005) (0)
- Effect of Interventions for Relapse or Progression Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience of 93 Patients. (2007) (0)
- Comparison of Outcomes After Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) In 73 Patients with Follicular Lymphoma (FL), Transformed Follicular Lymphoma (TL), or De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Favorable Outcome for TL Similar to FL (2010) (0)
- Engraftment Syndrome (ES) After Reduced-Intensity Stem Cell Transplantation (RIST): ES May Have a Negative Impact on Survival In Standard-Risk Patients (2010) (0)
- [Immunologic phenotype of malignant lymphoma]. (1992) (0)
- Evaluation of Cytomegalovirus (CMV)-Specific Cytotoxic T Lymphocyte (CTL) Monitoring Procedures with Tetramer and Intracellular IFN-γ Assay after Allogeneic Hematopoietic Stem Cell Transplantation (SCT). (2004) (0)
- Evaluation of Pre-Transplantation T-Cell Receptor Excision Circles (TREC) in Reduced-Intensity Stem Cell Transplantation (RIST) Recipients. (2006) (0)
- Dasatinib (SPRYCEL®, BMS-354825) Phase-I/II Study of Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib: Results of the CA180031 Study in Japan (Phase I Portion). (2006) (0)
- Oligonucleotide Microarray Analysis of Ocular Adnexal MALT Lymphoma with Trisomy 18. (2006) (0)
- An evaluation of mogamulizumab for the treatment of peripheral T-cell lymphoma (2014) (0)
- Phase I Study of a New Humanized Anti-CD20 Monoclonal Antibody (LY2469298) in Japanese Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL) Pretreated with Rituximab-Containing Regimen (2010) (0)
- [A clinical application of the revised European-American Lymphoma Classification for Prognostic and Therapeutic Purpose]. (1998) (0)
- [Lymphoid diseases:Overview]. (2012) (0)
- Analysis of Chimerism Induction Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Reduced-Intensity Regimen. (2004) (0)
- Phase II study of rituximab plus high-dose ara-C (HDAC)-containing chemotherapy (CTX) followed by ASCT in untreated mantle cell lymphoma (MCL): Japan Clinical Oncology Group study (JCOG0406). (2015) (0)
- 15. Treatment of Malignant Lymphoma (2008) (0)
- Impact of Hepatic Toxicities on Survival after Allogeneic Hematopoietic Cell Transplantation (HCT): Comparison of Reduced-Intensity Versus Conventional Conditioning Regimens at a Single Center. (2006) (0)
- Central Nervous System Invasion in Multiple Myeloma: A Nationwide Survey of 75 Patients in Japan (2016) (0)
- Acknowledgement to the Reviewers (2004) (0)
- High dose chemotherapy followed by autologous bone marrow transplantation (ABMT) and daily infusion of granulocyte colony stimulating factor (G-CSF) for malignant tumors in adults. (1991) (0)
- Imaging the Differential Engraftment of GFP-Expressing Spleen and Bone Marrow Cells in Various Organs after Reduced-Intensity Stem Cell Transplantation in Mice Model. (2006) (0)
- ISY-28-4Clinical development of BTK inhibitors in Japan (2016) (0)
- CLINICAL ASPECTS OF MARGINAL ZONE LYMPHOMA (1997) (0)
- Phase II trial of bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or elderly mantle cell lymphoma in Japan. (2016) (0)
- 108 – Adult T-Cell Leukemia-Lymphoma (2014) (0)
- Intrafollicular classical Hodgkin lymphoma mimicking nodular lymphocyte predominant Hodgkin lymphoma: A report of two cases (2014) (0)
- Ishida et al-2015-British Journal of Haematology (2016) (0)
- Molecular target therapy for malignant tumor 2) Molecular target treatment for hematopoietic tumor (3) The antibody therapy of malignant lymphoma. (2005) (0)
- Prognostic factors in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent autologous stem-cell transplantation (2016) (0)
- Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results (2017) (0)
- Serum Amyloid A (SAA) as a Molecular Marker for Pre-Engraftment Immune Reactions (PIR) after Cord Blood Transplantation. (2006) (0)
- [Lymphoid malignancies: progress in diagnosis and treatment. Topics: I. Pathogenesis and pathophysiology--recent findings; 2. Malignant lymphoma and related diseases]. (2011) (0)
- [Prognosis of non-Hodgkin's lymphoma. 1. T- and B-lymphomas and their primary sites]. (1985) (0)
- [Chemotherapy for malignant lymphoma in Western countries and Japan]. (1993) (0)
- PS1259 LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA (2019) (0)
- [Antitumor activity of human interferons: their direct cytotoxic activity and clinical effects]. (1983) (0)
- O1–066A MULTICENTER PHASE II STUDY OF MOGAMULIZUMAB (KW-0761) IN PATIENTS WITH RELAPSED PERIPHERAL OR CUTANEOUS T-CELL LYMPHOMA (2013) (0)
- Erratum to: A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia (2013) (0)
- Human T‐cell Lymphotropic Virus Type 1 Positive Adult T‐cell Leukemia/Lymphoma (2021) (0)
- [Cross and non-cross resistant anticancer agents to multidrug-resistant cultured cells from hematologic malignancies]. (1989) (0)
- [High dose chemotherapy with autologous bone marrow transplantation and G-CSF for hematologic malignancies]. (1992) (0)
- Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A (2021) (0)
- Therapeutic future direction with new clinical trials for refractory lymphoid malignancies (1997) (0)
- Aberrations of Genes Regulating NF Kappa B Pathway in B-Cell Malignant Lymphoma. (2009) (0)
- [Treatment of malignant lymphoma: an overview]. (2000) (0)
- A Meta-Analysis of Pivotal Pralatrexate Studies in Relapsed/Refractory Mature T-Cell Lymphoma (r/r TCL) (2021) (0)
- Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies (2022) (0)
- Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102). (2016) (0)
- Quality assurance of radiotherapy in the Japan Clinical Oncology Group trial 0211 concerning concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: The individual case review. (2006) (0)
- [Detection of multidrug resistant cells in human malignant diseases by monoclonal antibodies and strategy to eradicate resistant malignant cells]. (1989) (0)
- Influence of the Watch and Wait Strategy on the Clinical Outcome in Patients with Follicular Lymphoma in the Rituximab Era (2014) (0)
- [Antibody treatment of malignant lymphoma]. (2005) (0)
- [Detection of anti-ATLA (adult T-cell leukemia virus-associated antigen) in the sera of lymphoid malignancies in Kanto area]. (1983) (0)
- [Review of changes introduced by the new WHO classification (4th edition) of lymphoid malignancies. An overview]. (2009) (0)
- Randomized phase II study of concurrent and sequential combinations of rituximab (R) plus CHOP (R-CHOP) in untreated indolent B-cell non-Hodgkin's lymphoma (B-NHL). (2004) (0)
- Establishment andcharacterization of10cell lines derived from patients withadult T-eell leukemia (1983) (0)
- Ten-Year Follow-up of Newly Diagnosed Follicular Lymphoma Patients Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) As First-Line Therapy in JCOG0203 Trial (2017) (0)
- [How to improve the efficacy of R-CHOP for indolent B-cell lymphoma?]. (2012) (0)
- P3–010TESTICULAR AND LEPTOMENINGEAL RELAPSE AS MYELOID SARCOMA IN A PATIENT INITIALLY DIAGNOSED WITH T LYMPHOBLASTIC LYMPHOMA (2013) (0)
- Current Clinico-Epidemiological Characteristics of Adult T-Cell Leukemia-Lymphoma (ATL) Based on the 11th Nationwide Survey in Japan (2015) (0)
- Faculty Opinions recommendation of Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. (2012) (0)
- Managing the Risk of Hepatitis B Virus Reactivation in Patients with B-Cell Lymphomas Treated with Obinutuzumab or Rituximab Immunochemotherapy (2017) (0)
- Phase I study of once-weekly high-dose carfilzomib and dexamethasone (Cd) in Japanese patients with RRMM. (2018) (0)
- Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study (2022) (0)
- ANALYSIS OF PUBLISHED TREATMENT OPTIONS FOR RELAPSED OR REFRACTORY (R/R) PERIPHERAL T–CELL LYMPHOMA (PTCL): AN EVIDENCE BASED DECISION MAKING APPROACH (2019) (0)
- [Treatment strategy for indolent B-cell lymphoma]. (2001) (0)
- Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy (2021) (0)
- Conventional treatment of peripheral T-cell lymphoma: the Asian perspective (2009) (0)
- A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis (2022) (0)
- [Effect of combination chemotherapy with adriamycin in elderly non-Hodgkin's lymphoma patients]. (1988) (0)
- Quantification of MRD in rituximab plus CHOP (R-CHOP) therapy in follicular lymphoma (FL): Results of a randomized trial comparing the concurrent and sequential administrations. (2004) (0)
- A Distinct Entity of Ocular Adnexal MALT Lymphoma with Trisomy 18. (2005) (0)
- HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1) (2021) (0)
- [Radioimmunotherapy for B-cell lymphoma]. (2006) (0)
- The Impact of Concurrent Expression of MYC and BCL2 on Outcomes of Localized Primary Gastric Diffuse Large B-Cell Lymphoma Undergoing Rituximab-Containing Chemotherapy with or without Radiotherapy (2014) (0)
- Prognostic Value Of LMP1, CLA, NK-Cell Origin, and Pretreatment Bone Marrow EBER-ISH In Localized NK/T-Cell Lymphoma Prospectively Treated With Concurrent Chemoradiotherapy: An Ancillary Study Of Japan Clinical Oncology Group (JCOG) 0211 (2013) (0)
- Faculty Opinions recommendation of Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. (2011) (0)
- Japanese multicenter phase II study of CHOP followed by radiotherapy (RT) in stage I-II1 diffuse large B-cell lymphoma (DLBCL) of the stomach (2004) (0)
- [Malignant lymphoma: progress in therapeutics and cooperation between physicians and medical facilities. Discussion]. (2001) (0)
- Fever Following Bortezomib Administration Correlated with Serum Cytokine Levels in Patients with Multiple Myeloma (MM). (2006) (0)
- Outcome of Radiotherapy for Gastric MALT Lymphoma Resistant to Helicobacter pylori Eradication Therapy: A Retrospective Study of 43 Patients (2010) (0)
- Primary Treatment for Acute Graft-Versus-Host Disease (GVHD): A Single-Center Analysis of 458 Japanese Patients. (2007) (0)
- Attenuated Preemptive Therapy Against Cytomegalovirus (CMV) Reactivation/Disease Consisting of a Higher Cutoff Point and a Lower Initial Dose of Ganciclovir after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with an HLA-Identical Sibling Donor. (2004) (0)
- Viral infection Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation (2001) (0)
- Chromosomal Translocation (14;16)-Positive Multiple Myeloma Shows Negativity for CD56 Expression and Unfavorable Outcome Even in the Era of Novel Drugs (2014) (0)
- Faculty Opinions recommendation of Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. (2010) (0)
- Differences between Japan and rest of world (ROW) in disease presentation and outcome of previously treated adult t-cell leukemia-lymphoma (ATL) using therapy with a monoclonal antibody to CCR4, mogamulizumab (moga). (2016) (0)
- Circulating miRNA Profiling of Plasma Samples from Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study to Predict the Response and Toxicity of Bortezomib-Containing Regimen: An Ancillary Study of JCOG1105 (JCOG1105A1) (2022) (0)
- [Clinical evaluation of classifications of malignant lymphoma from the viewpoint of history]. (1998) (0)
- [The reaction specificity of various monoclonal antibodies against cultured cell lines derived from human leukemias and malignant lymphomas]. (1982) (0)
- Treatment and Prognosis in Patients with Adult T-Cell Leukemia-Lymphoma (ATL): A Nationwide Survey in Japan (2016) (0)
- [Treatment of B cell lymphoma by using monoclonal antibodies]. (2001) (0)
- 3) Human T-lymphotropic Virus Type-I and Adult T-cell Leukemia-lymphoma (2015) (0)
- Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results (2022) (0)
- Inotuzumab Ozogamicin in B-Cell Non-Hodgkin's Lymphoma Refractory to Rituximab + Chemotherapy or Radioimmunotherapy (2012) (0)
- Cytoreductive Regimen Containing Ranimustine (MCNU),Carboplatin, Etoposide and Cyclophosphamide (MCEC) Before Autologous Peripheral Blood Stem Cell Transplantation for Relapsed or Refractory Lymphoma (2008) (0)
- Phase II Study of Oral Fludarabine (FAMP) in Combination with Rituximab in Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) (2007) (0)
- Reduced-Intensity Stem Cell Transplantation (RIST) for Non-Hodgkin Lymphoma (NHL): A Single-Institute Experience of 52 Patients. (2004) (0)
- [112th Scientific Meeting of the Japanese Society of Internal Medicine: Symposium: Viral Infection and Tumors: Human T-lymphotropic Virus Type-I and Adult T-cell Leukemia-lymphoma]. (2015) (0)
- [New agent development for T-cell non-Hodgkin lymphoma: current status and future directions]. (2010) (0)
- A Phase I/II Study of Bortezomib in Combination with Melphalan and Prednisolone in Japanese Patients with Newly Diagnosed Multiple Myeloma (2011) (0)
- P3–014TRANSFORMED FOLLICULAR LYMPHOMA MIMICKING ACUTE LYMPHOBLASTIC LEUKEMIA (2013) (0)
- 388: Primary Treatment and Prognosis of Acute Graft-versus-host Disease (GVHD): A Single-center Analysis of 458 Patients (2008) (0)
- [Immunologic phenotype of acute leukemia, with reference to FAB classification of acute leukemia]. (1982) (0)
- Diffuse Large B-Cell Lymphoma with Extra BCL-2 Gene Signals Detected by FISH Analysis Is Associated with “Non-Germinal Center Phenotype” Defined by Immnohistochemistry. (2004) (0)
- [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma]. (2002) (0)
- High Frequency of Loss of Heterozygosity Due to Uniparental Disomy or Allele Deletion of Ocular Adnexal MALT-Type Lymphoma. (2007) (0)
- Faculty Opinions recommendation of Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. (2010) (0)
- Guideline for clinical safety data management in Japan Clinical Oncology Group (JCOG) (version 4) (2001) (0)
- [Antibody therapy of hematologic malignancies: present status and future directions]. (2004) (0)
- Fertility and social reintegration after modified CODOX‐M/IVAC with or without rituximab: A questionnaire survey of non‐Hodgkin lymphoma (2017) (0)
- 287: Hematopoietic Cell Transplantation (HCT) for Chemoradiotherapy-Related Myelodysplastic Syndrome and Acute Leukemia: A Single-Center Analysis of 47 Patients (2008) (0)
- Intravenacaval invasion of classical Hodgkin lymphoma detected with 18F-fluorodeoxyglucose (18F-FDG) PET-MRI. (2017) (0)
- Detection of drug resistance in human hematologic malignancy by monoclonal antibodies. (1988) (0)
- The Revised European-American Classification of Lymphoid Neoplasms: One Clinician's Comments. (1996) (0)
- Phase I/II Multicenter Study of Romidepsin in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (2016) (0)
- Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601 (2018) (0)
- ISY9-5Clinical trials for T/NK-cell lymphomas in Japan (2015) (0)
- Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study (2021) (0)
- [Diagnosis and treatment of angioimmunoblastic T-cell lymphoma]. (2012) (0)
- Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients (2021) (0)
- lymphoma not associated with human T cell leukemia virus type I Chromosome aberrations and clinical features of adult T cell leukemia (2011) (0)
- Treatment of B-cell non-Hodgkin's lymphoma with anti-CD20 monoclonal antibodies.:Treatment of B-cell non-Hodgkin's lymphoma with anti-CD20 monoclonal antibodies (2002) (0)
- Long-Term Outcome of ATL Patients Who Underwent Reduced-Intensity Stem Cell Transplantation (RIST): Suggested Potent Graft-Versus-ATL and HTLV-1 Effects. (2009) (0)
- Collection of Autologous Peripheral Blood Stem Cells (PBSC): Safety Evaluations during the Peri-Apheresis Period. (2004) (0)
- TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma (2021) (0)
- High Frequency of Engraftment Fever (EF) in Patients with Malignant Lymphoma (ML) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Reduced-Intensity Conditioning Regimen. (2004) (0)
- WS1. the expansion of surgical indication in gastric colorectal cancer drug therapy (2012) (0)
- 235: Hyperglycemia during neutropenia was associated with poor outcome in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) (2007) (0)
- Eight weekly infusions of rituximab (R) for relapsed patients (pts) with indolent B-cell lymphoma mostly pretreated with R: A Japanese multicenter phase II study. (2010) (0)
- Comparison of Outcomes after Reduced-Intensity Versus Myeloablative Stem Cell Transplantation in 128 Patients with Acute Myeloid Leukemia: A Single-Center Analysis. (2006) (0)
- An objective based model of published treatment options for relapsed or refractory (R/R) peripheral t-cell lymphoma (PTCL): An evidence-based decision-making approach. (2019) (0)
- Cytoreductive Regimen Containing Ranimustine (MCNU), Carboplatin, Etoposide and Cyclophosphamide (MCEC) Before Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Relapsed or Refractory Lymphoma (2009) (0)
- Long-term outcome of radiotherapy for mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa (2000) (0)
- ["Indolent B-cell lymphoma" based on the histologic review according to REAL classification]. (1998) (0)
- Quantification of MRD in rituximab plus CHOP (R-CHOP) therapy in follicular lymphoma (FL): Results of a randomized trial comparing the concurrent and sequential administrations (2004) (0)
- ASSESSMENT INDEX OF CLINICAL TRANSFORMATION FROM FOLLICULAR LYMPHOMA (FL) TO DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA (2017) (0)
- Graft-Versus-Tumor Effects after Allogeneic Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies. (2005) (0)
- Allogeneic Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies Not in Remission: The Anti-Tumor Effect of Reduced-Intensity Conditioning Is Comparable to That of Conventional Myeloablative Conditioning. (2005) (0)
- MO12-5 Phase III trial of bendamustine plus rituximab for relapsed or refractory diffuse large B-cell lymphoma in Japan (2021) (0)
- [VEPA therapy in B-lymphoma]. (1986) (0)
- Faculty Opinions recommendation of Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. (2009) (0)
- Genomics of Limited-Stage Diffuse Large B-Cell Lymphoma Developing Late Relapse: Analysis of Gene Alterations in Paired Primary and Late Relapsed Tumors By Target Sequencing (2018) (0)
- Anti-Tumor Activity of Low Dose Ocaratuzumab in Previously Treated Follicular Lymphoma Patients with Low-Affinity CD16 Polymorphisms (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kensei Tobinai?
Kensei Tobinai is affiliated with the following schools:
